- 3.9Impact Factor
- 6.8CiteScore
- 18 daysTime to First Decision
Special Issues
Sustainability publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process.
The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue polices and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.
Advances in Immune Cell Biology: Insights from Molecular Perspectives
Deadline: 31 March 2026
Noncoding RNAs (ncRNAs): The Role in Gene Regulation and Human Diseases
Deadline: 31 March 2026
Hepato-Pancreato-Biliary Cancers: Pathogenesis, Comorbidities and Therapy Updated
Deadline: 31 March 2026
Cholinergic System Neurodegeneration: Novel Pharmacotherapy
Deadline: 31 March 2026
Multidisciplinary Management of Rare Head and Neck Tumors: The Importance of Knowing and Dealing with Them
Deadline: 31 March 2026
Advanced Research in Antiviral Innate Immunity
Deadline: 31 March 2026
Connective Tissue Disorders: Pathogenetic, Diagnostic and Therapeutic Perspectives
Deadline: 31 March 2026
Drug Resistance and Tumor Microenvironment in Human Cancers
Deadline: 31 March 2026
New Horizons in Enzyme Inhibitor Discovery: Targets, Design and Evaluation
Deadline: 31 March 2026
Feature Reviews in Target Identification and Drug Discovery
Deadline: 31 March 2026
Epigenetics in the Perioperative Setting
Deadline: 31 March 2026
Roles of Extracellular Vesicles in Cancer Immunotherapy
Deadline: 31 March 2026
of 149

